Robert J. Flanagan

Robert J. Flanagan, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Sagent Pharmaceuticals, Inc., Martek Biosciences Corp and W. P. Carey Inc. In total, 73 filings cover trades dated from 10 April 2006 to 1 July 2025.

In open-market terms, that means 8 purchases worth €1.1M on one side and 23 sales worth €11.0M on the other. Taken together, the sales exceed the purchases by €10.0M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 12 share grants and 17 option exercises.

Half of the purchases are above €42k and half below.

On 2 July 2025 came the latest disclosure, a share grant in W. P. Carey Inc. The last purchase on record was published on 5 March 2020, which is 2,423 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.